Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed HIV positive test (2 rapid diagnostics tests (RDTs) followed by a confirmatory ELISA test).~* Diagnosis of VL (first episode or relapse) confirmed by bone marrow or spleen aspirate.~* Male and female age: 18-60 years.~* Written informed consent from the patient.~Exclusion Criteria:~* Women of child-bearing potential (defined as women who have achieved menarche) who are not using an assured method of contraception or are unwilling to use an assured method of contraception for the duration of treatment and four months after.~* Pregnant women or breast-feeding mothers.~* Patients with grade 2 or 3 post kala-azar dermal leishmaniasis (PKDL) lesions.~* Clinical or biological evidence of severe cardiac, renal or hepatic impairment.~* Known hypersensitivity to AmBisome® and/or miltefosine.~* Patients receiving allopurinol treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Liposomal Amphotericin B / Miltefosine (Type: EXPERIMENTAL): Liposomal Amphotericin B : 30mg/kg total dose: IV infusion 5mg/kg per day on day 1, 3, 5, 7, 9, 11~Miltefosine: orally taken every day during 28 days~* 1 x 50 mg capsule per day if patient weights less or equal to 25 kg~* 2 x 50 mg capsules per day if the patient weights more than 25 kg
- Liposomal Amphotericin B (Type: EXPERIMENTAL): Liposomal Amphotericin B: 40 mg/kg total dose : IV infusion of 5mg/kg per day on day 1 to 5, 10, 17, 24

Based on this trial design, predict the completion outcome and termination type (if applicable).